SRE
63
-3
KMX
58
3
IFF
53
2
URI
53
-2
WAT
47
5
DLTR
34
-4
EXC
54
-2
AIG
38
-4
T
50
3
IBM
54
4
SO
55
-2
INTU
51
2
HPE
55
11
RSG
68
3
NWSA
62
2
URBN
38
-4
COP
56
2
DTE
50
3
AFL
46
-3
LLY
39
9
SRE
63
-3
KMX
58
3
IFF
53
2
URI
53
-2
WAT
47
5
DLTR
34
-4
EXC
54
-2
AIG
38
-4
T
50
3
IBM
54
4
SO
55
-2
INTU
51
2
HPE
55
11
RSG
68
3
NWSA
62
2
URBN
38
-4
COP
56
2
DTE
50
3
AFL
46
-3
LLY
39
9
Financhill
Back

Cartesian Therapeutics 10K Form

Sell
26

RNAC
Cartesian Therapeutics

Last Price:
16.93
Seasonality Move:
13.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RNAC News And Ratings

See the #1 stock for the next 7 days that we like better than RNAC

RNAC Financial Statistics

Sales & Book Value

Annual Sales: $26M
Cash Flow: $7.49M
Price / Cash Flow: 0
Annual Sales: $0.03
Price / Book: 627.6

Profitability

EPS (TTM): -54.95000
Net Income (TTM): $-244.83M
Gross Margin: --
Return on Equity: 0%
Return on Assets: -79.52%

Cartesian Therapeutics Earnings Forecast

Key Cartesian Therapeutics Financial Ratios

  • The Research & Development expenses have been 276.26% of Revenue.
  • The Interest Expense is -1.29% of Operating Income.
  • The Net Earning history of RNAC is -844.91% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 6 years.

Cartesian Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RNAC
Website: cartesiantherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 10.7
Quick Ratio: 10.51

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RNAC Technical Analysis vs Fundamental Analysis

Sell
26
Cartesian Therapeutics (RNAC) is a Sell

Is Cartesian Therapeutics a Buy or a Sell?